Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3702569 | 0.83 | BACE1 (0.33) | — | |
| SCHEMBL1452116 | 0.81 | — | — | |
| SCHEMBL9889780 | 0.81 | — | — | |
| SCHEMBL18253594 | 0.81 | NOS3 (0.36) | ESR1 | |
| SCHEMBL24688166 | 0.79 | KCNH2 (0.43) | — | |
| SCHEMBL8528800 | 0.78 | — | — | |
| SCHEMBL10754466 | 0.78 | HTR1D (0.35) | — | |
| SCHEMBL25006844 | 0.77 | GPR84 (0.39) | — | |
| SCHEMBL11961153 | 0.75 | POLB (0.39) | — | |
| SCHEMBL3002699 | 0.75 | ALDH1A1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007012980-A1 | TOBACCO WITH AN INCREASED LEVEL OF NATURAL TAR DILUTENTS | PHILIP MORRIS PRODUCTS S.A. (CH) | 2007-02-01 | — | — | WO | claimed |
| US-20060283469-A1 | Tobacco with an increased level of natural tar diluents | PHILIP MORRIS USA INC. (US) | 2006-12-21 | — | — | US | claimed |
| US-20240208993-A1 | FIVE- AND SIX-MEMBERED COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | HANGZHOU POLYMED BIOPHARMACEUTICALS, INC. (CN) | 2024-06-27 | — | — | US | disclosed |
| US-20240025913-A1 | TERTIARY CARBOXAMIDE COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230174507-A1 | IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD. (IL) | 2023-06-08 | — | — | US | disclosed |
| US-20230015914-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2023-01-19 | — | — | US | disclosed |
| US-11377431-B2 | Inhibitors of RAF kinases | KINNATE BIOPHARMA INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-20220110933-A1 | METHODS OF TREATING DISEASE WITH MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2022-04-14 | — | — | US | disclosed |
| WO-2021216665-A9 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2021-12-02 | — | — | WO | disclosed |
| WO-2021216665-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2021-10-28 | — | — | WO | disclosed |
| US-11124537-B2 | Inhibitors of glucocorticoid receptor | ORIC PHARMACEUTICALS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20120121806-A1 | Complexes Of Imidazole Ligands | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| WO-2011156699-A1 | COMPLEXES OF IMIDAZOLE LIGANDS | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2011-12-15 | — | — | WO | disclosed |
| WO-2007012980-A1 | TOBACCO WITH AN INCREASED LEVEL OF NATURAL TAR DILUTENTS | PHILIP MORRIS PRODUCTS S.A. (CH) | 2007-02-01 | — | — | WO | disclosed |
| US-20060283469-A1 | Tobacco with an increased level of natural tar diluents | PHILIP MORRIS USA INC. (US) | 2006-12-21 | — | — | US | disclosed |
| EP-0332075-B1 | PROCESS FOR THE PREPARATION OF ACYLATED IMIDAZOLES | BASF Aktiengesellschaft (DE) | 1993-06-02 | — | — | EP | disclosed |
| EP-0300324-B1 | PROCESS FOR THE PRODUCTION OF ACYLATED IMIDAZOLES AND PYRAZOLES | BASF Aktiengesellschaft (DE) | 1992-07-22 | — | — | EP | disclosed |
| US-4924000-A | Preparation of acylated imidazoles | BASF AKTIENGESELLSCHAFT (DE) | 1990-05-08 | — | — | US | disclosed |
| EP-0332075-A1 | Process for the preparation of acylated imidazoles | BASF Aktiengesellschaft (DE) | 1989-09-13 | — | — | EP | disclosed |
| US-4056108-A | IMIDAZOLE OR BENZIMIDAZOLE, FLAVOR ENHANCERS | R. J. REYNOLDS TOBACCO COMPANY (US) | 1977-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174507-A1 | IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF | ACSS2, ADSS2, GLS2 | ESR1 2953/4885 |
| US-11124537-B2 | Inhibitors of glucocorticoid receptor | NR3C1, NR3C2, MC2R | ESR1 190/4885 |
| US-20220110933-A1 | METHODS OF TREATING DISEASE WITH MAGL INHIBITORS | MGLL, LIPA, PNLIP | ESR1 4824/4885 |
| US-20240025913-A1 | TERTIARY CARBOXAMIDE COMPOUNDS | YAP1, TFAM, PC | ESR1 1685/4885 |
| US-20120121806-A1 | Complexes Of Imidazole Ligands | ICOSLG, CLTC, PICALM | ESR1 4173/4885 |
| US-20240208993-A1 | FIVE- AND SIX-MEMBERED COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | IRAK4, FLT3, IRAK2 | ESR1 1925/4885 |
| US-20230015914-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC3R, MC1R, MC2R | ESR1 1856/4885 |
| US-11377431-B2 | Inhibitors of RAF kinases | BRAF, RAF1, ARAF | ESR1 2072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.